P53 | Use of monoclonal antibodies in pregnant women infected by COVID-19
P. Crispino1, R. Marocco2, D. Di Trento2, G. Guarisco1, B. Kertusha2, A. Carraro2, C. Pane3, L. Di Troia3, C. Del Borgo2, M. Lichtner4 | 1UOC Medicina Interna, Ospedale Santa Maria Goretti, Latina, 2UOC Malattie Infettive, Ospedale Santa Maria Goretti, Latina, 3UOC Ostetricia e Ginecologia, Ospedale Santa Maria Goretti, Latina, 4Dipartimento di Area Medica, Ospedale Santa Maria Goretti, Latina, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Monoclonal antibodies are designed to target specific proteins of COVID-19 and can be used as a treatment for people with mild to moderate infection and at a high risk of severe disease. Casirivimab/imdevimab, sotrovimab, and bamlanivimab/etesevimab have been authorized for emergency use in the treatment of COVID-19. However, during pregnancy, these drugs have not been extensively studied.
Methods: A total of 22 pregnant women with mild to moderate infection were treated with three different monoclonal antibodies, and efficacy and safety were evaluated in the first period and until six months of follow-up.
Results: No infusion/allergic reactions occurred. No fatal or adverse events were observed in the pregnant women or fetus. The time of negativization with sotrovimab was shorter in comparison to imdevimav/casirivimab (p=0.0187) and bamlanivimab/etesevimab (p <0.00001). The time of negativization with sotrovimab was earlier in comparison to imdevimav/casirivimab (t-value: 2.92; p=0.0052) in vaccinated patients and similar in comparison to Imdevimav/ casirivimab (t-value: 1.48; p=0.08). In unvaccinated patients, sotrovimab was faster to achieve negativization in comparison to Bamlanivimab/etesevimab (t-value: 10.75; p <0.0005).
Conclusions: Pregnant COVID-19 patients receiving sotrovimab obtained better clinical outcomes. Pregnancy or neonatal complications were not observed after monoclonal treatment, confirming the safety and tolerability of these drugs in pregnant women.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.